Figure 2 | Scientific Reports

Figure 2

From: PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer

Figure 2

Efficient cellular internalization of siRNA@PLGA NPs on MDR ovarian cancer cells. (A) Flow cytometric histogram showing cellular internalization of the fluorescent siRNA@PLGA NPs on SKOV3-TR and A2780-CP20 cancer cells respectively. The resistance cell lines were treated with fluorescent Cy5.5-siRNA@PLGA NPs, and 24 h later, sorted. A prefixed gate region was allowed only for Cy5.5 fluorescence. The untreated cells are indicated as a control. (B) Z-stack confocal microscopic images of SKOV3-TR and A2780-CP20 cancer cells treated with Cy5.5-labeled siRNA@PLGA NPs. Cy5.5-siRNA and DAPI dyes are represented by red and blue, respectively. Scale bar: 10 μm.

Back to article page